BioCryst Pharmaceuticals, Inc. (BCRX)

Check out top investors' recommendation for BCRX
Last closing price (N/A)
(0.00%) ? 
Last closing price is the stock price upon last market close (date specified in parenthesis).
Return to date (1m/3m/6m/12m):
N/A ? 
Return to date is the stock return for the specified period of time.
Consensus price target (1m/3m/6m/12m):
9.50
 ? 
Consensus price target is the average analyst price target for a specified period of time.
Buy/Sell Mix (1m/3m/6m/12m):
100%/0%
 ? 
Buy/sell mix the percentage mix between Buy and Sell recommendations for a given company or a research firm. Hold recommendations are excluded.
Description:
BioCryst Pharmaceuticals, Inc., a biotechnology company, designs, optimizes, and develops novel drugs that block key enzymes involved in the pathogenesis of diseases. The company integrates the disciplines of biology, crystallography, medicinal chemistry, and computer modeling to discover and develop small molecule pharmaceuticals through the structure-guided drug design process. Its product candidates include peramivir, an intravenous neuraminidase inhibitor, which is approved for seasonal influenza in Japan and Korea, as well as in Phase III clinical trials for acute influenza; ulodesine, an oral purine nucleoside phosphorylase inhibitor, which has completed Phase II clinical trials for the treatment of gout; and forodesine, an oral purine nucleoside phosphorylase inhibitor that is in Phase II clinical trials for oncology. Its pre-clinical compounds include BCX4161, an oral serine protease inhibitor for kallikrein hereditary angioedema; and BCX4430, a RNA dependent-RNA polymerase inhibitor for treating Filoviruses. The company has collaborative relationships with Mundipharma International Holdings Limited for the development and commercialization of forodesine; and Shionogi & Co., Ltd. and Green Cross Corporation for the development and commercialization of peramivir. Biocryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
Sector:
Industry:
Analyst
An analyst is a professional research analyst or an Investor Wand user who issued a recommendation for a given company.
Research Firm
A Research Firm is a company that researches and rates stocks and publishes recommendations.
Signal
Signal is a recommendation issued by an analyst. Investor Wand considers two types of recommendations: BUY and SELL.
Signal Date
A signal date is a date when a BUY or SELL recommendation was issued for given security.
Initial Price
Initial Price is the first closing price for a specified company upon recommendation release. If the recommendation is issued in after-market hours, the Initial Price is the next day’s closing price (for a given symbol). In case of dividend distributions and stock splits, Initial Price is adjusted.
Price Target
A Price Target is an analyst’s projection of a company’s stock price by the end of the recommendation period. It represents the price at which the analyst would exit his or her existing position.
Closing Date
Closing Date is the expiration date of a recommendation. The validity timeframe of a professional analyst’s recommendation is 12 months. Investor Wand analysts can set their recommendation timeframe to one, three, six, or 12 months.
Return
The return on a single open recommendation is calculated as the maximum of the current return (based on the latest closing price) and the target price return, if the symbol reached the target. The return on a single closed recommendation is calculated as the maximum of the return on the closing date (at the end of recommendation timeframe) and the target price return, if the stock hit the target price. The return is adjusted for one-time events (e.g., stock splits).
Jessica Fye JPMorgan Buy   Sep 06, '17     9.00  Sep 06, '18  N/A 
Andrew Fein Chardan Capital Markets Buy   Aug 08, '17     10.00  Aug 08, '18  N/A 
Mark Jordan Noble Financial Capital Mkts Buy   May 26, '17       May 26, '18  N/A 
Andrew Fein Chardan Capital Markets Buy   May 19, '17     10.00  May 19, '18  N/A 
Liisa Bayko JMP Securities Buy   Dec 16, '16       Dec 16, '17  N/A 
Rahul Jasuja Noble Financial Capital Mkts Buy   Feb 09, '16   1.89  8.00  Feb 09, '17  206.35% 
Andrew Fein Chardan Capital Markets Buy   Feb 09, '16   1.89  10.00  Feb 09, '17  206.35% 
Jorge Aura Unaffiliated Sell   Feb 08, '16   1.78  0.50  Aug 08, '16  -132.58% 
Brian Abrahams Wells Fargo Securities, Llc Buy   Jan 06, '16   9.65  14.00  Jan 06, '17  -28.19% 
Rahul Jasuja Noble Financial Capital Mkts Buy   Oct 12, '15   9.11    Oct 12, '16  N/A 
Andrew Fein Chardan Capital Markets Buy   Oct 09, '15   8.80  24.00  Oct 09, '16  -50.34% 
Charles Duncan Piper Jaffray Buy   Oct 08, '15   9.75  18.00  Oct 08, '16  -55.18% 
Steve Byrne BofA Merrill Lynch Buy   Jun 30, '15   14.93  19.00  Jun 30, '16  -80.51% 
Serge Belanger Needham & Company Buy   Mar 31, '15   9.03    Mar 31, '16  -69.66% 
Andrew Fein Chardan Capital Markets Buy   Feb 19, '15   10.12    Feb 19, '16  -79.84% 
Ed Arce Mcnicoll, Lewis, & Vlak Buy   Dec 16, '14   10.23    Dec 16, '15  -5.67% 
Steve Byrne BofA Merrill Lynch Sell   Dec 04, '14   9.92  8.00  Dec 04, '15  -2.32% 
Ed Arce Mcnicoll, Lewis, & Vlak Buy   Oct 31, '14   11.72    Oct 31, '15  -23.29% 
Ed Arce Mcnicoll, Lewis, & Vlak Buy   Aug 07, '14   12.90    Aug 07, '15  10.62% 
Brian Abrahams Wells Fargo Securities, Llc Buy   Jun 23, '14   12.00    Jun 23, '15  31.42% 
< previous12